


-TFW

Docket No: ENP-074 (4014.1074 US)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Yat Sun Or  
 Application No.: 10/763,377 Group Art Unit: 1623  
 Filed: January 23, 2004 Examiner: Not Yet Assigned  
 Confirmation No.: 7571  
 Title: Bridged Macrocyclic Compounds and Processes for the Preparation Thereof

CERTIFICATE OF MAILING OR TRANSMISSION I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or is being facsimile transmitted to the United States Patent and Trademark Office on:	
10/26/04 Date	 Signature
RACHEL MEEHAN Typed or printed name of person signing certificate	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment  
 Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is submitted:

- under 37 CFR 1.129(a), or  
(First/Second submission after Final Rejection)
- under 37 CFR 1.97(b), or  
(Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).
- under 37 CFR 1.97(c) together with either:
  - a Statement under 37 CFR 1.97(e), as checked below, or
  - a \$180.00 fee under 37 CFR 1.17(p), or  
(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
- under 37 CFR.1.97(d) together with:
  - a Statement under 37 CFR 1.97(e), as checked below, and
  - a \$180.00 fee under 37 CFR 1.17(p), or  
(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)
- under 37 CFR 1.97(i):  
Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper. (Filed after payment of issue fee)

Statement Under 37 CFR 1.97(e)

- Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

(Applies to original applications (other than design) filed on or after May 29, 2000)

- Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in -§ 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.
- Enclosed herewith is form PTO-1449:
- Copies of the cited references (AO-AL2) are enclosed.
- Since this application was filed after June 30, 2003, copies of issued U.S. patents and published U.S. applications are not required and are not being provided.
- Copies of cited references are enclosed except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]
- The listed references were cited in the enclosed International Search Report in a counterpart foreign application.
- The "concise explanation" requirement (non-English references) for reference(s) [ ] under 37 CFR 1.98(a)(3) is satisfied by:
- the explanation provided on the attached sheet.
- the explanation provided in the Specification.
- submission of the enclosed International Search Report.
- submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.
- the enclosed English language abstract.

The Examiner is requested to return a copy of the list of pending applications indicating which references were considered with the next office communication.


It is requested that the information disclosed herein be made of record in this application.

Method of payment:

- A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.
- Please charge Deposit Account  in the amount of [\$ ]. A copy of this Statement is enclosed.
- Please charge any deficiency in fees and credit any overpayment to Deposit Account 502807.

Respectfully submitted,


ELMORE CRAIG, P.C.

By   
Darlene A. Vanstone  
Registration No.: 35,729  
Telephone: (978) 251-3509  
Facsimile: (978) 251-3973

Chelmsford, MA 01863

Dated: 10/26/04

PTO-1449 REPRODUCED  <b>SUPPLEMENTAL                  INFORMATION DISCLOSURE CITATION                  IN AN APPLICATION</b>  October 19, 2004 (Use several sheets if necessary)	ATTORNEY DOCKET NO. ENP-074 (4014.1074 US)	APPLICATION NO. 10/763,377	
	FIRST NAMED APPLICANT Yat Sun Or		
	FILING DATE January 23, 2004	CONFIRMATION NO. 7571	GROUP 1623



U.S. PATENT DOCUMENTS				
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER	ISSUE DATE / PUBLICATION DATE	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
	AC	3,417,077	17-DEC-1968	H.W. Murphy <i>et al.</i>
	AD	5,780,605	14-JUL-1998	Or <i>et al.</i>

U.S. COPENDING APPLICATIONS				
EXAM- INER INI- TIAL	REF. NO.	APPLICATION SERIAL NUMBER	FILING DATE	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT

FOREIGN PATENT DOCUMENTS						
		DOCUMENT NUMBER	DATE	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO	
	AO	EP 0 238 178 A1	23-SEP-1987	Eli Lilly and Company		
	AP	WO 99/21864	06-MAY-1999	Abbott Laboratories		
	AQ	WO 03/095466 A1	20-NOV-2003	Enanta Pharmaceuticals, Inc.		
	AL2	WO 03/097659 A1	27-NOV-2003	Enanta Pharmaceuticals, Inc.		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		

EXAMINER	DATE CONSIDERED
----------	-----------------